Inclusion Criteria

          -  Patients must have untreated cervical biopsy-proven, CIN 2/3 ectocervical lesion(s).

          -  Patients must have satisfactory colposcopy with visualization of the entire
             transformation zone or a negative endocervical curettage if colposcopy is
             unsatisfactory.

          -  Patients must be high-risk HPV+ as determined by commercially available DNA
             hybridization test which tests for 13 high-risk HPV types.

          -  All Patients must have a histologic diagnosis of CIN 2,3 cervical lesion(s) confirmed
             by a study pathologist within past 10 weeks.

          -  Patients must have signed an approved informed consent.

          -  Patients of childbearing potential must have a negative urine pregnancy test within 7
             days prior to the study entry and be practicing an effective form of contraception.

          -  Patients must be at least 18 years of age based on previous and current cervical
             cancer screening guidelines.

          -  Patients must be fluent in speaking English or Spanish.

        Exclusion Criteria

          -  Patients with unsatisfactory colposcopy* (unable to visualize entire transformation
             zone) or evidence of endocervical disease defined as CIN 2/3 diagnosed on endocervical
             curettage.

             *Patients with unsatisfactory colposcopy but negative endocervical curettage are
             eligible

          -  Patients with a history of invasive cervical cancer

          -  Patients with a history of other invasive malignancies, with the exception of
             non-melanoma skin cancers are excluded if there is any evidence of other malignancy
             being present within the last five years. Patients are also excluded if their previous
             cancer treatment contraindicates this protocol therapy.

          -  Patients with any unstable medical issue (including cardiac issues as above, active
             treatment for pulmonary embolism, CVA, renal or hepatic insufficiency, active
             infection/sepsis requiring IV antibiotics).

          -  Patients who have an uncontrolled seizure disorder, or active neurological disease.

          -  Patients known to be seropositive for HIV and active hepatitis, even if liver function
             studies are in the normal range. Patients otherwise immunocompromised will also be
             excluded (chronic steroid use, taking immunosuppressive medications).

          -  Pregnant or breastfeeding patients.

          -  Patients who have had a total hysterectomy (removal of uterus and cervix) or
             trachelectomy (removal of cervix).

          -  Patients with a known hypersensitivity to imiquimod. Patients with a known
             hypersensitivity to any prophylactic HPV vaccine or severe allergic reactions yeast
             (vaccine component).

          -  Patients who have received their first dose of HPV vaccine < 4 weeks ago or their
             second dose < 12 weeks ago.

          -  Known hypersensitivity or prior intravaginal treatment with Imiquimod